AM
AMGXF.US AnGes Inc
- Market cap
- USD 144M
- P/E
- -
- P/B
- 0.73x
- ROE
- -2,639.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is AMGXF.US undervalued?
Graham numberThe Graham number of AnGes Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
AnGes Inc fundamental analysis
No fundamental analysis for AnGes Inc yet.
AnGes Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About AnGes Inc
AnGes, Inc. engages in the research and development of gene-based medicines. It develops HGF gene therapy product for the treatment of chronic arterial occlusive disease; NF-KB decoy oligonucleotide for chronic discogenic lumbar back pain; and DNA vaccines for the treatment of hypertension, as well as tie2 agonists for COVID-19/ARDS and drugs for chronic hepatitis B. AnGes, Inc. was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. The compan…
Full company profileAnGes Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
AnGes Inc annual financial statements (JPY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | 365M | 610M | 327M | 40.0M | 64.1M | 65.5M | 153M | 644M | 874M | 1.01B |
| Gross Profit | - | 187M | 422M | 240M | 17.0M | 7.43M | -25.2M | 19.4M | 248M | 320M | 475M |
| Operating Income | - | -3.29B | -3.07B | -3.27B | -5.60B | -15.6B | -15.9B | -12.0B | -9.11B | -5.15B | -6.47B |
| EBITDA | - | -3.26B | -3.06B | -3.26B | -4.19B | -13.2B | -13.4B | -8.86B | -5.74B | -5.09B | -5.20B |
| Net Income | - | -3.76B | -3.00B | -3.75B | -4.21B | -13.7B | -11.9B | -7.44B | -28.1B | -5.12B | -5.43B |
| EPS | - | -47 | -31 | -35 | -32 | -89 | -67 | -37 | -98 | -13 | -14 |
| Balance Sheet | |||||||||||
| Total Assets | - | 3.96B | 8.05B | 12.5B | 38.4B | 45.5B | 38.8B | 28.9B | 4.67B | 5.41B | 3.66B |
| Total Liabilities | - | 342M | 316M | 469M | 5.67B | 6.82B | 8.40B | 2.79B | 2.51B | 2.33B | 3.45B |
| Shareholders' Equity | - | 3.62B | 7.73B | 12.1B | 32.7B | 38.6B | 30.4B | 26.1B | 2.16B | 3.08B | 206M |
| Cash & Short-term Investments | - | 1.15B | 5.78B | 10.0B | 11.5B | 17.9B | 11.0B | 4.16B | 1.71B | 1.88B | 282M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -4.98B | -2.99B | -2.52B | -2.18B | -2.96B | -11.4B | -11.2B | -8.75B | -6.61B | -5.75B | - |
| Capital Expenditure | 0.00 | 7.00M | 50.0M | 6.00M | 80.0M | 80.0M | 19.0M | 89.3M | 77.5M | 14.3M | 0.00 |
| Free Cash Flow | - | -3.00B | -2.57B | -2.19B | -3.04B | -11.5B | -11.2B | -8.84B | -6.69B | -5.76B | - |
| Ratios | |||||||||||
| ROE | - | -103.9% | -38.7% | -31.1% | -12.9% | -35.4% | -39.2% | -28.5% | -1,304.3% | -166.6% | -2,639.5% |
| ROA | - | -95.0% | -37.2% | -29.9% | -11.0% | -30.1% | -30.7% | -25.7% | -602.5% | -94.8% | -148.3% |
| Net Profit Margin | - | -1,030.9% | -491.2% | -1,147.9% | -10,524.3% | -21,319.1% | -18,186.0% | -4,861.7% | -4,370.3% | -586.1% | -539.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
AnGes Inc dividends
AnGes Inc has not paid dividends in the last 9 fiscal years.
Who owns AnGes Inc
- Insiders 7.94%
- Institutions 2.92%
- Public & others 89.14%
- Shares outstanding 399M
- Free float 391M
AnGes Inc company profile
- Company name
- AnGes Inc
- Ticker
- AMGXF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 56
- Fiscal year end
- December
- Address
- Saito Bio-Incubator, Ibaraki, Japan, 567-0085
- Phone
- 81 72 643 3590
- Website
- anges.co.jp
About AnGes Inc
AnGes, Inc. engages in the research and development of gene-based medicines. It develops HGF gene therapy product for the treatment of chronic arterial occlusive disease; NF-KB decoy oligonucleotide for chronic discogenic lumbar back pain; and DNA vaccines for the treatment of hypertension, as well as tie2 agonists for COVID-19/ARDS and drugs for chronic hepatitis B. AnGes, Inc. was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. The company was incorporated in 1999 and is headquartered in Ibaraki, Japan.
AnGes Inc management
3- Dr. Ei Yamada M.D., Ph.D.CEO, President & Representative Director · born 1950
- Yuka MurakamiAccounting Department Manager
- Mr. Naoya SatoDirector of Administration & Director · born 1960